Gilead Sciences INC: insider trades · United States · SEC (Form 4)

About Gilead Sciences INC

GILEAD SCIENCES INC (ticker GILD) is a U.S.-listed biopharmaceutical company traded on the NASDAQ market in the United States, with headquarters in Foster City, California. Founded in 1987, Gilead has evolved into a global leader in therapies for serious and life-threatening diseases, with a strategic focus on three core therapeutic areas: virology, oncology, and inflammation. For international investors, the company stands out as a large-cap healthcare name combining established commercial franchises, substantial scientific capabilities, and a long-duration innovation pipeline. Gilead’s historical strength lies in virology, especially HIV and viral hepatitis. Its commercial portfolio includes major HIV brands such as Biktarvy and Descovy, alongside liver-disease therapies and Veklury for COVID-19-related treatment, although the latter has become less material to overall growth. In oncology, Gilead has expanded through Kite, its cell-therapy business, while inflammation has become an increasingly important pillar of the company’s R&D strategy. This broader therapeutic mix is strategically relevant because it reduces long-term dependence on a single franchise and creates additional avenues for growth. From a competitive standpoint, Gilead remains one of the most important players in HIV care, supported by strong brand recognition, deep clinical expertise and a broad global footprint. The company operates in more than 35 countries and markets more than 25 medicines worldwide. It also reports a sizable clinical pipeline across virology, oncology and inflammation, which is central to maintaining its relevance in a highly competitive pharmaceutical landscape. Gilead’s scale, manufacturing capabilities and partnerships give it the ability to compete with other large global pharma and biotech companies. Recent developments have been noteworthy. In 2026, Gilead reported full-year 2025 revenue of about USD 29.4 billion, with growth driven mainly by HIV and liver-disease products. The company highlighted progress around lenacapavir and announced access-oriented partnerships aimed at expanding availability in lower-income markets. Gilead has also continued investing in U.S.-based research and manufacturing, including new infrastructure at its Foster City headquarters, underscoring its long-term commitment to domestic innovation and supply-chain capacity. Overall, Gilead presents as a high-quality healthcare company with a mature cash-generating base and a pipeline that could support the next phase of growth.